NasdaqCM - Delayed Quote USD
XTL Biopharmaceuticals Ltd. (XTLB)
At close: November 6 at 4:00 PM EST
After hours: November 6 at 5:50 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
689.0000
765.0000
880.0000
1,031.0000
948.0000
Operating Income
-689.0000
-765.0000
-880.0000
-1,031.0000
-948.0000
Net Non Operating Interest Income Expense
44.0000
37.0000
25.0000
-13.0000
16.0000
Other Income Expense
267.0000
-1,054.0000
-493.0000
1,479.0000
-2,022.0000
Pretax Income
-378.0000
-1,782.0000
-1,348.0000
435.0000
-2,954.0000
Net Income Common Stockholders
-378.0000
-1,782.0000
-1,348.0000
435.0000
-2,954.0000
Average Dilution Earnings
--
--
--
-660.0000
--
Diluted NI Available to Com Stockholders
-378.0000
-1,782.0000
-1,348.0000
-225.0000
-2,954.0000
Basic EPS
-0.03
--
-0.20
0.10
-0.60
Diluted EPS
-0.03
--
-0.20
-0.04
-0.60
Basic Average Shares
5,449.0610
--
5,449.0610
5,319.9550
5,142.0580
Diluted Average Shares
5,449.1590
--
5,449.0910
6,155.4840
5,142.0580
Total Operating Income as Reported
-689.0000
-765.0000
-880.0000
-1,031.0000
-948.0000
Rent Expense Supplemental
--
12.0000
6.0000
15.0000
42.0000
Total Expenses
689.0000
765.0000
880.0000
1,031.0000
948.0000
Net Income from Continuing & Discontinued Operation
-378.0000
-1,782.0000
-1,348.0000
435.0000
-2,954.0000
Normalized Income
-645.0000
-728.0000
-855.0000
-703.8300
-932.0000
Interest Income
39.0000
41.0000
36.0000
8.0000
33.0000
Net Interest Income
44.0000
37.0000
25.0000
-13.0000
16.0000
EBIT
630.0000
-765.0000
-880.0000
-1,031.0000
-948.0000
EBITDA
630.0000
-765.0000
-879.0000
-1,030.0000
-947.0000
Reconciled Depreciation
--
--
1.0000
1.0000
1.0000
Net Income from Continuing Operation Net Minority Interest
-378.0000
-1,782.0000
-1,348.0000
435.0000
-2,954.0000
Total Unusual Items Excluding Goodwill
267.0000
-1,054.0000
-493.0000
1,479.0000
-2,022.0000
Total Unusual Items
267.0000
-1,054.0000
-493.0000
1,479.0000
-2,022.0000
Normalized EBITDA
363.0000
289.0000
-386.0000
-2,509.0000
1,075.0000
Tax Rate for Calcs
--
--
--
0.0002
--
Tax Effect of Unusual Items
--
--
--
340.1700
--
12/31/2020 - 9/1/2005
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
CANF Can-Fite BioPharma Ltd.
2.1900
0.00%
EVGN Evogene Ltd.
1.9300
-2.03%
CGEN Compugen Ltd.
1.7200
+4.88%
NVCT Nuvectis Pharma, Inc.
8.15
+9.69%
BLRX BioLineRx Ltd.
0.4530
+0.22%
LCTX.TA Lineage Cell Therapeutics, Inc.
325.70
+0.68%
MTLF.TA Matricelf Ltd
393.60
+1.10%
IBO Impact BioMedical Inc.
2.5990
-3.74%
PXMD PaxMedica, Inc.
0.1110
+16.84%
ONCT Oncternal Therapeutics, Inc.
1.7200
+6.17%